Evolution of a cytokine using DNA family shuffling

Nature Biotechnology

Volumn 17, Issue 8, 1999, Pages 793-797

  Chang, Chia Chun J ^a   Chen, Teddy T ^a   Cox, Brett W ^a   Dawes, Glenn N ^a   Stemmer, Willem P C ^a   Punnonen, Juha ^a   Patten, Phillip A ^a  

^a MAXYGEN INC   (United States)

Author keywords

Cytokines; DNA shuffling; Interferon; Molecular breeding; Pharmaceutical proteins

Indexed keywords

CYTOKINE; RECOMBINANT ALPHA2A INTERFERON;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOTECHNOLOGY; CHIMERA; CROSS BREEDING; DNA LIBRARY; DRUG SYNTHESIS; GENETIC VARIABILITY; IMMUNOGENICITY; INBREEDING; MITOSIS INHIBITION; MOLECULAR CLONING; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHO CELLS; CRICETINAE; DNA; ENCEPHALOMYOCARDITIS VIRUS; EVOLUTION, MOLECULAR; HUMANS; INTERFERON-ALPHA; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; SEQUENCE HOMOLOGY, AMINO ACID;

ANIMALIA; MURINAE;

EID: 0032866310     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/11737     Document Type: Article

References (32)

1. Sprang, S.R. & Bazan, J.F. Cytokine structural taxonomy and mechanisms of receptor engagement. Cure Opin. Struct. Biol. 3, 815-827 (1993).
2. Dusheiko, G. Side effects of alpha Interferon in chronic hepatitis C. Hepatology 26, 112S-121S (1997).
3. Vial, T. & Descotes, J. Clinical toxicity of the interferons. Drug Experience 10, 115-150 (1994).
4. Funke, I. et al. Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. Ann. Hematol. 68, 49-52 (1994).
5. Schomburg, A., Kirchner, H. & Atzpodien, J. Renal, metabolic and hemodynamic side-effects of interleukin-2 and /or Interferon alpha: evidence of a risk /benefit advantange of subcutaneous thereapy. J. Cancer Res. Clin. Oncol. 119, 745-755 (1993).
6. Henco, K. et al. Structural relationship of human Interferon alpha genes and pseudogenes. J. Mol. Biol. 185, 227-260 (19B5).
7. Horisberger, M.A. & Di Marco, S. Interferon-alpha hybrids. Pharmacol. Ther. 66, 507-534 (1995).
8. Blatt, L.M., Davis, J.M., Klein, S.B. & Taylor, M.W. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus Interferon. J. Interferon Cytokine Res. 16, 489-499 (1996).
9. Stemmer, W.P.C. Searching sequence space. Biotechnology 13, 549-555 (1995).
10. Patten, P.A., Howard, R.H. & Stemmer, W.P.C. Applications of DNA shuffling to pharmaceutical and vaccines. Curr. Opin. Biotechnol. 8, 724-733 (1996).
11. Crameri, A., Raillard, S.A., Bermudez, E. & Stemme, R.W.P. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature 15, 288-291 (1998).
12. Uze, G., Lutfalla, G. & Mogensen, K.E. Alpha and beta interferons and their receptor and their friends and relations. J. Interferon Cytokine Res. 15, 3-26 (1995).
13. Burbank, L. in Luther Burbank, his methods and discoveries: their practical application Vol. 1 (eds Whitson, J. & Williams, R.J.H.S.) 176-210 (Luther Burbank Press, New York; 1914).
14. Haldane, J.B.S. A mathmatical theory of natural and artificial selection Cambridge Phil. Soc. Trans. 23, 19-41 (1924).
15. Muller, H.J. The relation of recombination to mutational advance. Mutat. Res. 1, 2-9 (1964).
16. Moore, J.C., Jin, H. & Arnold, F.H. Strategies for the in vitro evolution of protein function: enzyme evolution by random recombination of improved sequences. J. Mol. Biol. 272, 336-347 (1997).
17. Tymms, M.J., McInnes, B., Alin, P., Linnane, A.W. & Cheetham, B.F. Structure-function studies of intertefon-alpha based on random mutagenesis and expression in vitro. Genet. Anal. Techn. Appl. 7, 53-63 (1990).
18. van der Meide, P.H. & Schellekens, H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy 10, 39-48 (1997).
19. Konrad, M. Immunogenicity of proteins administered to humans for therapeutic purposes. Trends Biotechnol. 7, 175-179 (1989).
20. Allegreta, M. et al. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J. Clin. Immunol. 6, 481-490 (1986).
21. Lynch, M. & Wallace, B. in Genetics and analysis of quantitative traits (Sinauer Associates, Sunderland, MA; 1998)
22. Fun, G. et al. Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677-1630 (1992).
23. Lowman, H.B. & Wells, J.A. Affinity maturation of human growth hormone by monovalent phage display. J. Mol. Biol. 234, 564-578 (1993).
24. Thomas, J.W. et al. Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant interleukin 3. Proc. Natl. Acad. Sci. USA 92, 3779-3783 (1995).
25. Wells, J.A. Additivity of mutational effects in proteins. Biochemistry 29, 8509-8517 (1990).
26. Weber, H., Valaenzuela, D., Lujber, G., Gubler, M. & Weissmarin, C. Single amino acid changes that render human IFN-alpha 2 biologically active on mouse cells. EMBO. J. 6, 591-598 (1987).
27. Fish, E.N. Definition of receptor binding domains in interferon-alpha. J. Interferon Res. 12, 257-266 (1992).
28. Uze, G. et al. Domains of interaction between alpha Interferon and its receptor components. J. Mol. Biol. 243, 245-257 (1994).
29. Gutterman, J.U. Cytokine therapeutics: lessons from Interferon alpha. Proc. Natl. Acad. Sci. USA. 91, 1198-1205 (1994).
30. Klaus, W., Gsell, B., Labhardt, A.M., Wipf, B. & Senn, H. The three-dimensional high resolution structure of human Interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J. Mol. Biol. 274, 661-675 (1997).
31. Sambrook, J., Fritsch, E.F. & Maniatis, T. in Molecular cloning: a laboratory manual (Cold Spring Harbor Laboratory Press, New York; 1989).
32. Scarozza, A.M., Collins, T.J. & Evans, S.S. DNA synthesis in nuclei isolated from Daudi B cells: a model to study the antiproliferative mechanisms of Interferon alpha. J. Interferon Res. 12, 35-42 (1992).